6,620 reports of this reaction
4.7% of all PEGINTERFERON ALFA 2A reports
#3 most reported adverse reaction
ANAEMIA is the #3 most commonly reported adverse reaction for PEGINTERFERON ALFA 2A, manufactured by pharmaand GmbH. There are 6,620 FDA adverse event reports linking PEGINTERFERON ALFA 2A to ANAEMIA. This represents approximately 4.7% of all 141,362 adverse event reports for this drug.
PEGINTERFERON ALFA 2A has an overall safety score of 85 out of 100. Patients taking PEGINTERFERON ALFA 2A who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is moderately reported among PEGINTERFERON ALFA 2A users, representing a notable but not dominant share of adverse events.
In addition to anaemia, the following adverse reactions have been reported for PEGINTERFERON ALFA 2A:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 6,620 FDA reports for PEGINTERFERON ALFA 2A. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 4.7% of all adverse event reports for PEGINTERFERON ALFA 2A, making it one of the most commonly reported side effect.
If you experience anaemia while taking PEGINTERFERON ALFA 2A, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.